For Researchers
Biobanque Québec COVID-19 JGH Site Second Samples Release
We are pleased to announce the availability of biological samples from the Jewish General Hospital site of the Biobanque Québec COVID19 (BQC19) for use by researchers at academic institutions, within industry and from all countries. The JGH site has collected PBMC samples from 890 individuals at different time points (for a total of 1472 samples) and Plasma samples from 1317 individuals at different time points (for a total of 2304 samples) who were tested with SARS-CoV-2 nasal swabs at the JGH.
The JGH has elected to share these samples with researchers through the MI4 program, which will use an independent, external peer review committee to decide how to use these samples.
Please send your completed application to the following email address: bcq19imi4.med [at] mcgill.ca
Ìý
Biobanque Québec COVID-19 Data Release 3
The JGH Site of the Biobanque Québec COVID-19 (bqc19.ca) has collected samples and/or data from over 1428 individuals. The following data from BQC19 JGH site participants will be released in the third data release for use by approved investigators:
- Clinical variables on available individuals: ~1428
- Genome-wide genotyping data on available individuals: 1232
- Whole genome sequence data on available individuals: 1106
- SomaLogic proteomic data generated on 800 samples, collected longitudinally on 378 individuals
This data release process will be managed by The Â鶹Çø Interdisciplinary Initiative in Infection and Immunity (MI4) and is being released rapidly to enable COVID-19 research.
Applications for access to data are encouraged from investigators at academic institutions, within industry and from all countries.
Interested parties should fill out the Access Form and send to bcq19imi4.med [at] mcgill.ca
Description of Biobanque Québec COVID-19 JGH Site third Data Release and Access Procedures
Ìý
Biobanque Québec COVID-19 Data Release 2
The JGH Site of the Biobanque Québec COVID-19 (bqc19.ca) has collected samples and/or data from over 768 individuals. Extensive phenotypic data and Whole-Genome-Sequence data from BQC19 JGH site participants will be released in the second data release for use by approved investigators. This data release process will be managed by The Â鶹Çø Interdisciplinary Initiative in Infection and Immunity (MI4) and is being released rapidly to enable COVID-19 research.
Applications for access to data are encouraged from investigators at academic institutions, within industry and from all countries.
Interested parties should fill out the Access Form and send to bcq19imi4.med [at] mcgill.ca
For more information about the Biobank go to /genepi/mcg-covid-19-biobank
Description of Biobanque Québec COVID-19 JGH Site Second Data Release and Access Procedures
Co-Host of Â鶹Çø Summer Institute in Infectious Diseases and Global Health
MI4 is proud to co-host the . The 5th Annual Summer Institute took place between June 10-21, 2019 on Â鶹Çø campus. The Summer Institute brings together academics, students, seasoned physicians, industry professionals, policymakers, advocates, and former patients to learn, discuss, network and build collaborations. In 2018, almost 700 people participated in the 8 interactive courses providing new knowledge, lively discussions and hands-on learning experiences. The 2019 InstituteÌý featured an expanded course on antimicrobial resistance (AMR) led by MI4 AMR Theme Leader Dr Makeda Semret. The Summer Institute’s unique platform continues to attract top-notch faculty and learners from around the world.
Ìý
Ìý
Partnership with Â鶹Çø International TB Centre
MI4 supported the Â鶹Çø International TB Centre to deliver an intensive clinical training course on TB to 50 frontline health professionals (nurses and physicians) in Nunavut. The course, which took place in Iqaluit in April 2019, is tailored to the Nunavut context and focuses on TB prevention, treatment and care. It is being delivered at the request of the Government of Nunavut, following the successful initial delivery of the course in Montreal in 2018. In the coming year, we will work to expand and deliver this training course to caregivers in Nunavik.
Â鶹Çø Clinical Innovation Competition (CLIC)
The MI4 Innovation Prize, sponsored by MI4, was one of four prizes in the 2019 Â鶹Çø Clinical Innovation Competition (CLIC). The prize aims to support innovative solutions that focus on infectious and immune threats to human health. One winning team was selected in May 2019 amongst the 12 submissions, by the Â鶹Çø Clinical Innovation Competition panelists. Read about the winning team below!
Ìý
ANTIBIOTIC SENTINEL: Choosing the right antibiotic to treat a life-threatening bacterial infection is essential to patient care. Antibiotic sentinel is a web-based application that provides up-to-the-minute information to help doctors select the best antibiotic to maximize the chance of curing an infection while minimizing harmful side effects. This novel tool will immediately aid the care of patients presenting with serious bacterial infections and eventually learn to predict them. (Todd C. Lee, Emily G. McDonald, Louis Mullie, Jonathan Hershon, Christophe Marois)
